US 11,679,082 B2
Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
Wassana Yantasee, Lake Oswego, OR (US); Moataz Reda, Portland, OR (US); and Worapol Ngamcherdtrakul, Portland, OR (US)
Assigned to Oregon Health & Science University, Portland, OR (US); and PDX Pharmaceuticals, Inc., Portland, OR (US)
Filed by Oregon Health & Science University, Portland, OR (US); and PDX Pharmaceuticals, Inc., Portland, OR (US)
Filed on Nov. 23, 2021, as Appl. No. 17/534,415.
Application 17/534,415 is a continuation of application No. 17/023,311, filed on Sep. 16, 2020, granted, now 11,224,573.
Application 17/023,311 is a continuation of application No. PCT/US2020/041852, filed on Jul. 13, 2020.
Claims priority of provisional application 62/873,770, filed on Jul. 12, 2019.
Prior Publication US 2022/0071906 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/14 (2006.01); A61K 31/519 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 9/143 (2013.01) [A61K 9/146 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); C07K 16/2827 (2013.01); A61K 9/0019 (2013.01); B82Y 5/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A therapeutic construct comprising:
a mesoporous silica nanoparticle (MSNP) comprising platform loaded with:
a small molecule mitotic kinase inhibitor in an amount 0.01% to 5% by weight of the therapeutic construct, or a mitotic kinase-specific siRNA; and
a Programmed Death-Ligand 1 (PD-L1) antibody conjugated onto the MSNP platform.